CCL17 and hepatocellular carcinoma: Furthermore, there is no definitive evidence to determine whether CCL17 might be an independent target for cancer therapy or whether it might cooperate with other effective immune checkpoint inhibitors to enhance the anti-tumor effect in HCC.